FDA Grants MUMS Status to AB Science’s Masivet for Canine Tumors
Event summary
- FDA granted Minor Use in Major Species (MUMS) designation to Masivet® for treating canine mast cell tumors.
- MUMS status provides seven years of exclusive marketing rights upon approval and eligibility for grants to support clinical studies.
- Masivet® is already profitable in Europe but not yet registered in the USA.
- AB Science aims to expand Masivet® globally, including discussions for distribution agreements in LATAM, Asia, and MENA regions.
The big picture
The MUMS designation is a strategic milestone for AB Science, positioning Masivet® for potential U.S. market entry. The designation aligns with broader trends in veterinary medicine, where targeted therapies are gaining traction. If successful, Masivet® could become a key revenue driver, helping AB Science reduce reliance on human drug development pipelines.
What we're watching
- Regulatory Execution
- Whether AB Science can leverage the MUMS designation to secure FDA approval and expand Masivet® in the U.S. market.
- Revenue Diversification
- The pace at which AB Science can grow its animal health franchise to offset fixed costs and reduce financial risk.
- Global Expansion
- How successful AB Science will be in securing distribution agreements in untapped regions like LATAM, Asia, and MENA.
Related topics